Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Novacyt S.a. LSE:NCYT London Ordinary Share FR0010397232 EUR1/15TH (CDI)
  Price Change % Change Share Price Shares Traded Last Trade
  19.00 4.63% 429.00 682,483 16:35:17
Bid Price Offer Price High Price Low Price Open Price
430.00 440.00 440.00 410.00 410.00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 13.08 -3.91 -14.00 303
Last Trade Time Trade Type Trade Size Trade Price Currency
16:39:04 O 8,674 430.00 GBX

Novacyt (NCYT) Latest News

More Novacyt News
Novacyt Takeover Rumours

Novacyt (NCYT) Discussions and Chat

Novacyt Forums and Chat

Date Time Title Posts
27/9/202000:00CV and The Deep State83
26/9/202022:51COVID-1932,362
22/9/202023:58NCYT million's19
19/9/202015:36coronavirusTransmission facts vs fiction401
14/9/202012:07Novacyt SA shares soar on Coronavirus test kit.672

Add a New Thread

Novacyt (NCYT) Most Recent Trades

No Trades
Trade Time Trade Price Trade Size Trade Value Trade Type
View all Novacyt trades in real-time

Novacyt (NCYT) Top Chat Posts

DateSubject
26/9/2020
09:20
Novacyt Daily Update: Novacyt S.a. is listed in the Health Care Equipment & Services sector of the London Stock Exchange with ticker NCYT. The last closing price for Novacyt was 410p.
Novacyt S.a. has a 4 week average price of 295p and a 12 week average price of 252.50p.
The 1 year high share price is 517.50p while the 1 year low share price is currently 6.75p.
There are currently 70,626,248 shares in issue and the average daily traded volume is 944,223 shares. The market capitalisation of Novacyt S.a. is £302,986,603.92.
25/9/2020
20:28
bobdown2: Bountyhunter. Sharechat.ncyt is not membership unless you want to post!!. The gasmans twitter post showing the winterplex French approval has excited quite a few people tonight. You can imagine the French market on Monday if this is indeed true. Winterplex is the new panel and checks for flu and some other infections. The share price will really react. Shorters will be locked in or drive the share price up as they try to exit.
22/9/2020
19:09
bobdown2: Sometimes those that look at a share chart and see a really good rise see only an opportunity to drive the share price down and they go short. The t.w cess pit is one and apparently voleon are another. To make it work..share prophets anyway, is writing made up stories of dubious nature that bear no resemblance to what is happening to the company in the hope that their 99p members join them to take on some of their risk. The majority of c.f.d contracts lose money. That is why you see fresh articles from t.w every time the share price rises and they try to get their 99 pence fodder to take on their risk. It is a shame that the financial industries allow these financial sites the ability to bully normal investors.. in allot of cases with the investors own shares. The upside on here is there is loads of news flow due and it keeps proper investors waiting for the next company progress. Ours is the antibody test due within days.?? Ncyt has grown over 2000% and revenue has increased 1000% in the last six months. The CEO is still the same, the difference now is the sheer amount of avenues from where news can appear from. That's why there are going to be two lots of egg on faces. An algorithm face and a t.w.. they are nothing in comparison to the novacyt CEO.
21/9/2020
13:53
bobdown2: Care must be taken. Where a share price can drift after news this one has not priced in the revenues yet. An rns with revenues attached an a move up in the share price before the opening could prove costly.
17/9/2020
16:25
bunz3: graet post this routy be good if rns soon on mid cap move Routy17 Sep '20 - 12:18 - 31547 of 31583 0 6 0 Great Post from HillSeeker on LSE Spot on! True Value: £1bn, share price £15 Everyone has spotted the headline of predicted £100m expected profit for the year. GM is clearly being very cautious about predictions. As many of you have pointed out, this is simply a doubling of H1 rather than quadrupling of Q2, which would still be cautious; would we not expect July and August sales to be grater than June? And then continue to grow into the autumn with the shortage of testing and on-set of winter? Not to mention operation Moonshot. GM does say that sales are excepted to continue into 2021 as we would all now predict. So I think it would be safe to say that future earnings are more likely to annualised at closer to £200m. As has also been frequently pointed out on this board, share price is held back, as we don't know when the Covid sales will stop. But, clearly, GM has a plan to replace Covid sales long term: "Novacyt also plans to accelerate revenues and additional profitability through selective and accretive (sic) acquisitions. These actions are expected to replace any potential lost revenues from a future decline in COVID-19 testing." IMO this is not unreasonable considering the expansion of this global market: "With an estimated global market size of $69.5 billion in 2020, the IVD industry is set to experience steady growth and continued consolidation. Growing at a 5-year CAGR of 5%, some analysts expect IVD to top $110 billion1 by 2030." Altogether, I don't think this is sufficient to maintain a PE of 10 or 20 but a PE of say 6 would be very reasonable. 6 x £200m gives us £1.2bn and with 70.6 m shares a price of £17, which is in line our target of 1bn company at PS £15. Although most of this is not new news, it will attract more PR and, with a new broker, institutional investors will start to be attracted and the share price will continue its trajectory. US sales: You have to scroll down a fair way to see a table showing distribution by geographical area. It shows US sales in first half of year at approx £3.7m. This seems a difficult market to crack and GM talks about reviewing the strategy here: "... it is in the process of evaluating the best model to operate in the US." "Primerdesign's revenue includes approximately €21,000,000 (2019: € nil) from sales to the Group's largest customer. One other customer contributed 10% or more to the Group's revenue in 2020." Largest customer = UK Gov, 2nd largest = US or Germany? Finally, the provision for remuneration of certain employees (one assumes GM included) has been significantly increased: "As a result of the share price increasing significantly since December 2019, the provision for the long-term incentive plan for management has increase substantially to €4,187,000 as at 30 June 2020." But note, this is based on the share price at 30th June (259p), so with the share price now closer to £4, and increasing, this will need to be adjusted significantly further. GM is clearly a clever chap and this is going to go only in one direction between now and October 17th.
17/9/2020
13:10
bunz3: yes routy ,a great post from hillseeker Routy17 Sep '20 - 12:18 - 31547 of 31556 0 5 0 Great Post from HillSeeker on LSE Spot on! True Value: £1bn, share price £15 Everyone has spotted the headline of predicted £100m expected profit for the year. GM is clearly being very cautious about predictions. As many of you have pointed out, this is simply a doubling of H1 rather than quadrupling of Q2, which would still be cautious; would we not expect July and August sales to be grater than June? And then continue to grow into the autumn with the shortage of testing and on-set of winter? Not to mention operation Moonshot. GM does say that sales are excepted to continue into 2021 as we would all now predict. So I think it would be safe to say that future earnings are more likely to annualised at closer to £200m. As has also been frequently pointed out on this board, share price is held back, as we don't know when the Covid sales will stop. But, clearly, GM has a plan to replace Covid sales long term: "Novacyt also plans to accelerate revenues and additional profitability through selective and accretive (sic) acquisitions. These actions are expected to replace any potential lost revenues from a future decline in COVID-19 testing." IMO this is not unreasonable considering the expansion of this global market: "With an estimated global market size of $69.5 billion in 2020, the IVD industry is set to experience steady growth and continued consolidation. Growing at a 5-year CAGR of 5%, some analysts expect IVD to top $110 billion1 by 2030." Altogether, I don't think this is sufficient to maintain a PE of 10 or 20 but a PE of say 6 would be very reasonable. 6 x £200m gives us £1.2bn and with 70.6 m shares a price of £17, which is in line our target of 1bn company at PS £15. Although most of this is not new news, it will attract more PR and, with a new broker, institutional investors will start to be attracted and the share price will continue its trajectory. US sales: You have to scroll down a fair way to see a table showing distribution by geographical area. It shows US sales in first half of year at approx £3.7m. This seems a difficult market to crack and GM talks about reviewing the strategy here: "... it is in the process of evaluating the best model to operate in the US." "Primerdesign's revenue includes approximately €21,000,000 (2019: € nil) from sales to the Group's largest customer. One other customer contributed 10% or more to the Group's revenue in 2020." Largest customer = UK Gov, 2nd largest = US or Germany? Finally, the provision for remuneration of certain employees (one assumes GM included) has been significantly increased: "As a result of the share price increasing significantly since December 2019, the provision for the long-term incentive plan for management has increase substantially to €4,187,000 as at 30 June 2020." But note, this is based on the share price at 30th June (259p), so with the share price now closer to £4, and increasing, this will need to be adjusted significantly further. GM is clearly a clever chap and this is going to go only in one direction between now and October 17th
17/9/2020
12:18
routy: Great Post from HillSeeker on LSE Spot on!True Value: £1bn, share price £15Everyone has spotted the headline of predicted £100m expected profit for the year. GM is clearly being very cautious about predictions. As many of you have pointed out, this is simply a doubling of H1 rather than quadrupling of Q2, which would still be cautious; would we not expect July and August sales to be grater than June? And then continue to grow into the autumn with the shortage of testing and on-set of winter? Not to mention operation Moonshot.GM does say that sales are excepted to continue into 2021 as we would all now predict.So I think it would be safe to say that future earnings are more likely to annualised at closer to £200m.As has also been frequently pointed out on this board, share price is held back, as we don't know when the Covid sales will stop. But, clearly, GM has a plan to replace Covid sales long term:"Novacyt also plans to accelerate revenues and additional profitability through selective and accretive (sic) acquisitions. These actions are expected to replace any potential lost revenues from a future decline in COVID-19 testing."IMO this is not unreasonable considering the expansion of this global market: "With an estimated global market size of $69.5 billion in 2020, the IVD industry is set to experience steady growth and continued consolidation. Growing at a 5-year CAGR of 5%, some analysts expect IVD to top $110 billion1 by 2030."Altogether, I don't think this is sufficient to maintain a PE of 10 or 20 but a PE of say 6 would be very reasonable. 6 x £200m gives us £1.2bn and with 70.6 m shares a price of £17, which is in line our target of 1bn company at PS £15.Although most of this is not new news, it will attract more PR and, with a new broker, institutional investors will start to be attracted and the share price will continue its trajectory.US sales: You have to scroll down a fair way to see a table showing distribution by geographical area. It shows US sales in first half of year at approx £3.7m. This seems a difficult market to crack and GM talks about reviewing the strategy here: "... it is in the process of evaluating the best model to operate in the US.""Primerdesign's revenue includes approximately €21,000,000 (2019: € nil) from sales to the Group's largest customer. One other customer contributed 10% or more to the Group's revenue in 2020."Largest customer = UK Gov, 2nd largest = US or Germany?Finally, the provision for remuneration of certain employees (one assumes GM included) has been significantly increased: "As a result of the share price increasing significantly since December 2019, the provision for the long-term incentive plan for management has increase substantially to €4,187,000 as at 30 June 2020."But note, this is based on the share price at 30th June (259p), so with the share price now closer to £4, and increasing, this will need to be adjusted significantly further. GM is clearly a clever chap and this is going to go only in one direction between now and October 17th.
15/9/2020
09:08
bunz3: with so much testing being discussed in media ,could we see a nice update today on contracts ,were yesterdays large buyers hoping for news , be good if news to move ncyt share price back up to around £5 for the people holding around that share price
14/9/2020
17:29
bunz3: another blue day ,while share price moved up( 0,75% )2,5 p per share , still a move upwards ,when one looks at share account each move helps . another day closer to rns more sellers cleared at this level and replaced with buyers ,some happy with their profits ,others pleased to see them taking profits today ,so they could pick up their shares at as low a share price as possible .
31/8/2020
17:45
bountyhunter: No not really but I am expecting a progressive increase in the NCYT share price over the next few weeks as their latest developments result in orders from PrimerDesign's large global customer base. O/t actually I'm kicking myself for selling out of a few other Covid shares rather too early and will not be making that mistake with Novacyt. Doing ok with SAR though which is now nearly 50% up on my PB investment.
28/8/2020
09:24
bunz3: FRANCE share price now back up to 336 euro September looking like a big month for ncyt share price move up The Company is therefore finalising the development of its own two gene target test and expects to launch this two gene test no later than September 2020. 2,000 patient clinical trial using Novacyt's near-patient testing system initiated in London care homes AGM WEBCAST / Shareholders will be able to view a live webcast of the AGM Half Year Results GLOBAL SALES TO AROUND 130 COUNTRIES US NEWS In the US, the Company has signed a major distribution agreement for its COVID-19 test with a new global strategic partner. The US is delivering significant sales growth for Novacyt and this new agreement enables the Company to accelerate penetration of its COVID-19 test in this important market. This distribution agreement will focus initially on the US, with the potential to expand into further markets.
Novacyt share price data is direct from the London Stock Exchange
ADVFN Advertorial
Your Recent History
LSE
NCYT
Novacyt
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200927 05:28:59